The Shigella human challenge model
- PMID: 22906296
- PMCID: PMC9152033
- DOI: 10.1017/S0950268812001677
The Shigella human challenge model
Abstract
Shigella is an important bacterial cause of infectious diarrhoea globally. The Shigella human challenge model has been used since 1946 for a variety of objectives including understanding disease pathogenesis, human immune responses and allowing for an early assessment of vaccine efficacy. A systematic review of the literature regarding experimental shigellosis in human subjects was conducted. Summative estimates were calculated by strain and dose. While a total of 19 studies evaluating nine strains at doses ranging from 10 to 1 × 1010 colony-forming units were identified, most studies utilized the S. sonnei strain 53G and the S. flexneri strain 2457T. Inoculum solution and pre-inoculation buffering has varied over time although diarrhoea attack rates do not appear to increase above 75-80%, and dysentery rates remain fairly constant, highlighting the need for additional dose-ranging studies. Expansion of the model to include additional strains from different serotypes will elucidate serotype and strain-specific outcome variability.
Figures
Similar articles
-
The fusion subunit vaccine L-DBF protects aged mice against heterologous lethal Shigella challenge after prior exposure.Front Immunol. 2025 Jun 5;16:1586537. doi: 10.3389/fimmu.2025.1586537. eCollection 2025. Front Immunol. 2025. PMID: 40539050 Free PMC article.
-
A newly developed oral infection mouse model of shigellosis for immunogenicity and protective efficacy studies of a candidate vaccine.Infect Immun. 2025 Jan 31;93(1):e0034624. doi: 10.1128/iai.00346-24. Epub 2024 Dec 18. Infect Immun. 2025. PMID: 39692481 Free PMC article.
-
Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei.mSphere. 2021 Aug 25;6(4):e0012221. doi: 10.1128/mSphere.00122-21. Epub 2021 Jul 14. mSphere. 2021. PMID: 34259559 Free PMC article.
-
Shigellosis in Southeast Asia: A systematic review and meta-analysis.Travel Med Infect Dis. 2023 Mar-Apr;52:102554. doi: 10.1016/j.tmaid.2023.102554. Epub 2023 Feb 16. Travel Med Infect Dis. 2023. PMID: 36792021
-
Causative species and serotypes of shigellosis in mainland China: systematic review and meta-analysis.PLoS One. 2012;7(12):e52515. doi: 10.1371/journal.pone.0052515. Epub 2012 Dec 20. PLoS One. 2012. PMID: 23285073 Free PMC article.
Cited by
-
Further characterization of Shigella-specific (memory) B cells induced in healthy volunteer recipients of SF2a-TT15, a Shigella flexneri 2a synthetic glycan-based vaccine candidate.Front Immunol. 2023 Oct 31;14:1291664. doi: 10.3389/fimmu.2023.1291664. eCollection 2023. Front Immunol. 2023. PMID: 38022674 Free PMC article.
-
Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.PLoS One. 2018 Mar 28;13(3):e0194325. doi: 10.1371/journal.pone.0194325. eCollection 2018. PLoS One. 2018. PMID: 29590182 Free PMC article.
-
Shigella-Controlled Human Infection Models: Current and Future Perspectives.Curr Top Microbiol Immunol. 2024;445:257-313. doi: 10.1007/82_2021_248. Curr Top Microbiol Immunol. 2024. PMID: 35616717 Free PMC article. Review.
-
Effect of wild-type Shigella species and attenuated Shigella vaccine candidates on small intestinal barrier function, antigen trafficking, and cytokine release.PLoS One. 2014 Jan 9;9(1):e85211. doi: 10.1371/journal.pone.0085211. eCollection 2014. PLoS One. 2014. PMID: 24416363 Free PMC article.
-
The increasing antimicrobial resistance of Shigella species among Iranian pediatrics: a systematic review and meta-analysis.Pathog Glob Health. 2023 Oct;117(7):611-622. doi: 10.1080/20477724.2023.2179451. Epub 2023 Feb 16. Pathog Glob Health. 2023. PMID: 36794800 Free PMC article.
References
-
- Riddle MS, et al. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. American Journal of Tropical Medicine and Hygiene 2006; 74: 891–900. - PubMed
-
- Shaughnessy HJ, et al. Experimental human bacillary dysentery; polyvalent dysentery vaccine in its prevention. Journal of the American Medical Association 1946; 132: 362–368. - PubMed
-
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177–188. - PubMed
-
- Van de Verg LL, et al. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Vaccine 1996; 14: 1062–1068. - PubMed